Ondansetron Augmentation in Treatment-resistant OCD

• Status: Completed
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to evaluate whether ondansetron augmentation to SSRI will improve and ondansetron discontinuation will result in worsening of obsessive compulsive symptoms among obsessive compulsive disorder resistant patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Institute of Neuroscience, Florence, Italy
• Treatments: Ondansetron; Serotonin; Serotonin Uptake Inhibitors

Criteria

Inclusion Criteria:

• a diagnosis of OCD established by clinical interview with a licensed psychiatrist;

• a score of ≥ 24 at the Yale Brown Obsessive Compulsive Scale

• a Clinical Global Inventory score ≥ 4, after over 12 weeks of treatment with an adequate trial of an selective serotonin reuptake inhibitor at a moderate to high dose

Exclusion Criteria:

• diagnoses of schizophrenia, schizoaffective disorder, organic mental disorder, bipolar disorder, current substance dependence or abuse, and current major depressive episode preceding the onset of obsessive compulsive disorder

• undergoing concomitant behavior therapy

• or having significant cardiovascular, hepatic, renal or pulmonary diseases